



Published in final edited form as:

*Infect Control Hosp Epidemiol.* 2015 August ; 36(8): 886–892. doi:10.1017/ice.2015.115.

## The Likelihood of Hospital Readmission among Patients with Hospital-Onset Central Line-Associated Bloodstream Infections

Carolyn Khong, MPH<sup>1</sup>, James Baggs, PhD<sup>2</sup>, David Kleinbaum, PhD<sup>2,3</sup>, Ronda Cochran, MPH<sup>2</sup>, and John A. Jernigan, MD MPH<sup>2</sup>

<sup>2</sup>Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA

<sup>3</sup>Rollins School of Public Health, Emory University, Atlanta, GA

### Abstract

**Objective**—We sought to determine whether central line-associated bloodstream infections (CLABSI) increase the likelihood of readmission.

**Design**—Retrospective matched cohort study for the years 2008–2009.

**Setting**—Acute care hospitals.

**Participants**—Medicare recipients. CLABSI and readmission status were determined by linking National Healthcare Safety Network surveillance data to the Centers for Medicare & Medicaid Services' Medical Provider and Analysis Review in eight states. Frequency matching was used on ICD-9-CM procedure code category and intensive care unit status.

**Methods**—We compared the rate of readmission among patients with and without CLABSI during an index hospitalization. Cox proportional hazard analysis was used to assess rate of readmission (the first hospitalization within 30 days post-index discharge). Multivariate models included the following covariates: race, sex, length of index hospitalization stay central line procedure code, GAGNE co-morbidity score, and individual chronic conditions.

**Results**—Of the 8,097 patients, 2,260 were readmitted within 30 days (27.9%). The rate of first readmission was 7.1 events/person-year (PY) for CLABSI patients and 4.3 events/PY for non-CLABSI patients ( $p < 0.001$ ). The final model revealed a small but significant increase in the rate of 30 day readmissions for patients with a CLABSI compared to similar non-CLABSI patients. In the first readmission for CLABSI patients, we also observed an increase in diagnostic categories consistent with CLABSI including septicemia and complications of a device.

**Conclusions**—Our analysis found a statistically significant association between CLABSI status and readmission, suggesting that CLABSI may have adverse health impact that extends beyond hospital discharge.

---

Corresponding author: James Baggs, 1600 Clifton Road MS: A31, Atlanta, GA 30333, Ph: 404-543-8122, Fax: 404-639-8834, jbaggs@cdc.gov.

<sup>1</sup>Mrs. Khong is now currently affiliated with CHOC Children's Hospital, Orange, CA but completed the majority of the work while at CDC, Atlanta, GA

The authors presented an earlier version of this manuscript as a poster at IDWeek in San Francisco, in 2013.

**Potential conflicts of interest:** All authors report no conflict of interest relevant to this article.

## Introduction

Readmissions to acute care hospitals create a burden for patients and their health, accounting for increased costs, resources, and time for healthcare providers, payers, and ultimately the healthcare system.

Despite making progress, healthcare-associated infections (HAI) continue to impact patients in the United States. One in 25 hospital patients develop at least one HAI during hospitalization.<sup>1</sup> Estimates suggest HAIs result in \$28 to \$34 billion in excess healthcare costs each year.<sup>2</sup> Although the number of central line-associated bloodstream infections (CLABSI) has decreased over the last decade,<sup>3,4</sup> it is estimated over 30,000 occur nationally in hospital wards and critical care units. CLABSIs may lead to longer hospital stays, increased mortality, and increased costs.<sup>5–8</sup>

Readmissions or re-hospitalizations are challenging because they occur frequently and are costly to payers such as Medicare.<sup>9,10</sup> Rates of hospital readmission among adults can vary from five to 29%<sup>11–15</sup> and are responsible for up to 60% of hospital expenditures.<sup>16</sup> Prior research indicates there exists an association between having an HAI and becoming re-hospitalized. In one single center study, HAI incidents were the cause of 14.3% of readmissions.<sup>17</sup>

The ongoing problem of hospital readmissions continues to result in serious public health consequences by creating a burden on patients and generating unnecessary healthcare costs. Previous studies of CLABSI have focused on the visit in which the CLABSI occurred and do not examine the issue of readmission. The purpose of this analysis was to determine whether an association exists between patients identified as having a CLABSI and subsequent readmission to acute care hospitals.

## Methods

We conducted a retrospective cohort study for the years 2008–2009 to compare the rate of hospital readmissions among those with a hospital-onset CLABSI to frequency matched controls. Since, as previously shown, ICD-9-CM codes are not sufficiently able to identify CLABSI cases in administrative files,<sup>18</sup> we linked data from the National Healthcare Safety Network (NHSN) to identify CLABSI cases among a population of hospitalized Medicare enrollees identified from the Medicare Provider Analysis and Review (MedPAR) database and Beneficiary Annual Summary File (BASF) obtained from the Centers for Medicare & Medicaid Services (CMS). The methods for linking NHSN and MedPAR datasets to identify individual Medicare recipients with an HAI and frequency matching of uninfected patients have been previously described.<sup>19–21</sup> The CDC Human Research Protection Office determined this work was exempt from the regulations under 45 CFR 46.101(b)(5). This work was conducted under a data use agreement with CMS.

## Data Sources and Linkage

Cases of hospital-onset CLABSI were identified using data extracted from the NHSN CLABSI surveillance module for admissions. CLABSIs were defined according to the

standard NHSN protocol. Laboratory-confirmed bloodstream infections not secondary to another HAI were considered to be central line associated if a central line or umbilical catheter was in place at the time or within 48 hours before the onset of the infection.<sup>22</sup> Admission dates, date of birth, sex, facility and its location, and date of infection were captured electronically. For this analysis, only MedPAR data from 2008–2009 were available to us from Colorado, Illinois, New Hampshire, New York, Pennsylvania, South Carolina, Tennessee, and Virginia, chosen due to their participation in NHSN. The MedPAR database contains claims for beneficiaries from certified inpatient hospitals and skilled nursing facilities.<sup>23</sup> Only claims from inpatient hospital stays were included. This database along with the BASF provided information on admission dates, date of birth, sex, and facility for linking as well as information on diagnosis and procedures using ICD-9-CM codes, reimbursement cost of the claim, beneficiary status, and CMS chronic conditions. An encrypted beneficiary identifier was available in to order to follow beneficiaries longitudinally and determine their readmission status including readmission to other facilities. Unique healthcare facilities from the NHSN facility file were mapped to the CMS provider ID using the reported CMS provider ID when available or facility name and location from NHSN and data from the CMS Cost Reports, 2004–2009.

For both data sources, we limited the population to those over the age of 64 with a valid date of admission from January 2008 through December 2009, a valid date of birth, sex, and facility. In the MedPAR file, patients were also limited to those who aged into the Medicare recipient cohort with or without end stage renal disease, were enrolled in Medicare Part A and B throughout their eligibility, and never enrolled in a Medicare Advantage (HMO) program. We also eliminated hospital visits to certain special units such as psychiatric and swing units. To identify individuals with CLABSI, CLABSI events reported to NHSN were linked to hospital claims data in MedPAR using a combination of four variables including hospital admission date, date of birth, sex, and unique facility identifier.<sup>19,21</sup> Only unique, exact matches among those variables were included in the analysis.

### Control Selection and Frequency Matching

To control for potential confounding, first, potential controls were limited to the same facilities, age, primary ICD-9-CM diagnoses, and diagnosis-related groups (DRGs) observed in the population of patients with CLABSI. Patients with a diagnosis consistent with CLABSI (ICD-9-CM 999.31) but not identified as NHSN cases were eliminated from the potential control pool. Second, five non-CLABSI control stays were selected such that the frequency of the primary ICD-9-CM procedure category, based on single level Clinical Classification Software (CCS) available from the Agency for Healthcare Research and Quality (<http://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp>),<sup>24</sup> and intensive care unit (ICU) status were similar between CLABSI stays and non-CLABSI stays.<sup>21</sup> Therefore, patients with CLABSI (as reported to NHSN) made up our exposed group, while frequency matched controls without CLABSI made up our unexposed group for comparison.

### Outcome

Hospital readmissions occurring 1–30 days after the initial hospital discharge (index hospitalization) represented the primary outcome of the study. Patients discharged from their

index hospitalization and readmitted on the same day were considered transfers and excluded from the analysis along with patients who died during the index hospitalization. We also considered the first hospital readmission after the index hospitalization regardless of timing of readmission as a secondary outcome.

### Statistical Analysis

For univariate analysis, we used  $\chi^2$  test for dichotomous outcome measures, and Fisher's Exact test as appropriate. T-tests and Wilcoxon-rank sum were used for continuous variables. Potential confounders and interaction terms were assessed in both stratified and multivariable analyses. Potential interaction terms were assessed in the stratified analysis using the Breslow-Day test.

To assess the association between CLABSI and the rate of first re-hospitalization, the rate of initial readmission among those with a CLABSI and those without was compared through survival analysis using a Cox proportional hazard model. Patients were censored at death or the end of 30 days for the primary analysis. For our secondary outcome, time was allowed to accumulate from the time of discharge until readmission, death, or the end of the study period. Multivariate models included terms for age, race, sex, index hospitalization length of stay (LOS), presence of an ICD-9-CM procedure code for insertion of a central line, individual CMS chronic conditions, and indication of ICU care. These terms were based on the patient's index hospital stay. Given that the co-morbidity score<sup>25</sup> violated the proportional hazards assumptions, models were stratified by co-morbidity score. The final model was determined by assessing potential confounding in the multivariate models using methods previously described by Kleinbaum, et. al.<sup>26</sup> For the final models, all the terms but the CMS chronic conditions terms were included. In addition, because certain terms were found to be significant effect modifiers by the Breslow-Day test in the stratified analyses, a secondary analysis was conducted to evaluate those terms in multivariate Cox proportional hazard models. Two significant interaction terms, index hospitalization LOS and the CMS chronic condition rheumatoid arthritis, were included in the final model. Confounding was assessed as previously, and all terms including the CMS chronic conditions were included in those models.

In addition, to compare the potential reasons for readmission, we examined the frequency of the most common ICD-9-CM primary diagnosis category for the first readmission visit by CLABSI status. Differences in frequencies by CLABSI status were assessed using  $\chi^2$  test or Fisher's Exact test as appropriate. We also examined the frequency of patients discharged and readmitted within the same day by CLABSI status along with admission type for the subsequent stay.

Analyses were conducted using SAS 9.3 statistical software (SAS Institute, Cary, NC). Alpha was set to 0.05 for all statistical analyses.

### Results

MedPAR and NHSN data from eight states were linked to determine which individuals in the MedPAR dataset experienced a CLABSI during hospitalization. In those eight states,

there were over 3.95 million MedPAR records available and 4,747 CLABSI events among patients >64 years of age reported to NHSN. Of those 4,747, 41% (1,967) of NHSN records linked to a MedPAR inpatient hospital claim record. Given the proportion of persons >64 who use Medicare as the primary payer, who are enrolled in both Parts A and B and not the Medicare Advantage program and have aged into the Medicare cohort, only 49.8% or 2,364 NHSN events were expected to link. Therefore, our adjusted linkage rate is 83.2% (1,967/2,364). After limiting potential controls to those claims with same facilities, age range, range of primary ICD-9-CM diagnoses, and range of DRGs, 1.05 million non-CLABSI patients remained eligible to be selected as controls. After frequency matching, 9,835 controls were randomly selected for 1,967 cases, resulting in a total of 11,802 patients selected for the study. For all selected patients, hospital readmissions after discharge from the index hospitalization were identified.

Among the 11,802 patients, 8,097 patients survived the index hospitalization and were not transferred or re-hospitalized on the same day of discharge (Table 1). Among the 8,097, 917 (11.3%) had a CLABSI during the index visit and 7,180 did not have a CLABSI (88.7%). Demographics and clinical characteristics varied among those with and without a CLABSI (Table 1).

Overall, 2,260 of these patients (27.9%) were readmitted within 30 days (Table 1). Of the 917 with CLABSI, 340 (37.1%) were readmitted within 30 days compared to 26.7% among non-CLABSI,  $p < 0.0001$ . The rate of readmission within 30 days was 7.1 events per person-year (PY) for those with CLABSI. Among non-CLABSI patients, the rate of readmission in 30 days was 4.3 events/PY. Therefore, the rate of readmission within 30 days was 1.7 times higher among CLABSI patients compared to patients without a CLABSI [IDR=1.7, 95% CI (1.5, 1.9)]. In addition, 550 (60.0%) of those with a CLABSI and 3,962 (55.2%) of those without a CLABSI were ever readmitted during the study period, resulting in overall readmission rates of 2.5 events/PY and 1.4 events/PY respectively. The overall rate of readmission was 1.8 times higher for those with a CLABSI [IDR=1.8, 95% CI (1.6, 1.9)].

When adjusting for potential confounders, our Cox proportional hazards model demonstrated a borderline significant association between CLABSI and 30 day readmission [IDR=1.2, 95% CI (1.0, 1.3)]. We also observed a borderline association between CLABSI and all readmissions in the Cox proportional hazards model [IDR=1.1, 95% CI (1.0, 1.2)]. In addition, we examined the ten most common primary ICD-9-CM discharge CCS categories for the first readmission visit by CLABSI status (Table 2). Septicemia was the most common diagnosis category for readmission among those with a CLABSI and was reported over twice as often compared to those without CLABSI,  $p < 0.0001$ . Complications of a device, urinary tract infections, and intestinal obstruction without hernia were also more commonly reported among those with a CLABSI. In total, the most common primary categories account for 63% of the readmission events among those with a CLABSI.

In our secondary analysis which included potential effect modifiers, the final stratified Cox models demonstrated a statistically significant association between CLABSI and readmission to an acute care hospital modified by the effect modifiers LOS and rheumatoid arthritis (Table 3). As the index visit's LOS decreased, the rate of readmission for those with

a CLABSI increased compared to those without a CLABSI. For example, for CLABSI patients with LOS  $\leq 6$  days, the rate of readmission within 30 days was 5.5 to 7.5 times greater than patients without a CLABSI. A positive history of rheumatoid arthritis also increased the hazard ratio for readmission. However, for patients without a history of rheumatoid arthritis and a LOS  $> 6$  days, the rate of readmission within 30 days was not significantly higher for CLABSI patients compared non-CLABSI patients. When analyzing all readmissions during the study period, the hazard ratios decreased slightly compared to 30 day readmissions.

While our primary analysis eliminated those patients who were discharged and readmitted on the same day, patients with a CLABSI were more likely to be discharged and readmitted on the same day. Of the 1,239 CLABSI cases that did not die in the hospital, 321 (25.9%) were discharged and readmitted on the same day while only 856 (10.6%) of the 8,055 non-CLABSI cases were readmitted,  $p < 0.0001$ . Of those admitted on the same day as discharge, those with a CLABSI were more likely to have an urgent or emergency readmission (33% vs. 23%,  $p = 0.0004$ ).

## Discussion

In our study, CLABSI was determined to be significantly associated with readmission to an acute care hospital. Further, readmission rates were highest among patients with shorter LOS during their index visit or a history of rheumatoid arthritis. While our study focuses specifically on CLABSI, our findings are consistent with previous studies suggesting that HAIs may increase the risk of re-hospitalizations and have adverse health impact and burden that extends beyond hospital discharge.<sup>17,27-29</sup>

It is important to note there are few studies specifically examining the issue of CLABSI and hospital readmissions. Although the results are statistically significant, further research is needed, especially among different populations to determine the consistency of these findings. If confirmed, our findings further reinforce the need to prevent CLABSI, as this may benefit beyond the index visit though the total burden of readmissions attributable to CLABSI may not be large.

Our analysis also identified LOS and a diagnosis of rheumatoid arthritis as potential effect modifiers. Few studies have established relationships between re-hospitalization and LOS, as well as between re-hospitalization and rheumatoid arthritis. Kaboli et al. concluded that patients with an increased LOS had a higher likelihood of readmission, a three percent increase for every one extra day of stay.<sup>30</sup> In our analysis, a longer LOS during the index hospital stay was also associated with a higher rate of re-hospitalization (data not shown), but if a patient was exposed to CLABSI in the index hospitalization, a shorter LOS indicated a higher rate of readmission compared to those without a CLABSI but similar LOS (Table 3). We also found that exposure to CLABSI increased rate of re-hospitalization among patients diagnosed with rheumatoid arthritis (Table 3). The reasons for this association are unclear. Future studies could examine the potential interaction between LOS and rheumatoid arthritis with readmission following CLABSI as well as possible mechanisms for effect modification.

Our study had a number of strengths. First, NHSN and MedPAR data were linked to identify patients who were both infected with CLABSI and re-hospitalized. Therefore, we did not depend on the patients' ICD-9-CM codes to identify CLABSI, which previous research has shown their inability to properly differentiate HAIs.<sup>30,31</sup> In fact, one study found that administrative data often misclassified non-CLABSI cases as true CLABSI cases, producing a different number of cases compared to that of surveillance data.<sup>18</sup> Studies using only ICD-9-CM codes for identification of CLABSI suffer from strong misclassification bias in determining the exposure status. Also, data for readmissions were based on beneficiary claims in the MedPAR dataset, which are reliable for identifying longitudinal visits for beneficiaries even across different facilities, and also provide additional demographic and clinical information valuable for risk adjustment. Further, when we examined the primary diagnosis code of the first readmission, among those with a previous CLABSI, we observed an increase in diagnostic categories consistent with CLABSI including septicemia and complications of a device.

A limitation of our analysis is the inability to differentiate between a true, unplanned re-hospitalization and a planned hospital visit following discharge. It is possible or even likely that some of the readmissions included in the analysis represent planned readmission. However, the frequency of planned readmission would not be expected to have varied by CLABSI status given the frequency matching in the cohort. Hence any potential bias would be non-differential and bias towards the null. Further, because administrative data was used, we are unable to specifically determine how the preceding CLABSI was potentially related to the increase in the rate of readmissions. In addition, administrative data are not collected for research purposes, and therefore, misclassification may occur for other data derived from the MedPAR data source.<sup>32,33</sup> Another limitation is the potential for mismatches in the NHSN and MedPAR data linkage. By using specific requirements and allowing for only exact matches among our linkage variables, the likelihood of a mismatch is rare. Further since CLABSIs are rare and we eliminated patients who did not link but had an ICD-9-CM code consistent with CLABSI, it is unlikely our controls experienced a CLABSI. Again, such misclassification would have biased our results toward the null. Additionally, while we attempted to control for confounding through matching and multivariate models, there is potential for unmeasured confounding to exist in our analysis given the availability of data elements in our data sources. Finally, as the finding of the effect modifiers LOS and rheumatoid arthritis were unexpected, our control selection did not take this finding into account, and while our results would not be expected to be biased, future studies of readmission and HAI should consider the role of LOS into the design of the study.

In conclusion, our study found a significant association between CLABSI and the risk of readmission to an acute care hospital. Prevention of CLABSI may therefore reduce patient burden and healthcare costs associated not only with hospitalizations during which CLABSIs occur,<sup>2,33,34</sup> but also by prevention of a proportion of subsequent readmissions to the hospital and their associated costs.

## Acknowledgements

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

**Financial support:** None reported.

## References

1. Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. *N Engl J Med*. 2014; 370(13):1198–1208. [PubMed: 24670166]
2. Scott II RD. The Direct Medical Costs of Healthcare-Associated Infections in U.S. Hospitals and the Benefits of Prevention. Centers for Disease Control and Prevention; 2009.
3. Wise ME, Scott RD 2nd, Baggs JM, et al. National estimates of central line-associated bloodstream infections in critical care patients. *Infect Control Hosp Epidemiol*. 2013; 34(6):547–554. [PubMed: 23651883]
4. 2012 National and State Healthcare-Associated Infections Progress Report. Centers for Disease Control and Prevention; 2014 Mar 26.
5. Jarvis WR. Selected Aspects of the Socioeconomic Impact of Nosocomial Infections: Morbidity, Mortality, Cost, and Prevention. *Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America*. 1996; 17(8):552–557.
6. Stone PW, Braccia D, Larson E. Systematic Review of Economic Analyses of Health Care-Associated infections. *American journal of infection control*. 2005; 33(9):501–509. [PubMed: 16260325]
7. Shannon RP, Patel B, Cummins D, Shannon AH, Ganguli G, Lu Y. Economics of central line--associated bloodstream infections. *American journal of medical quality : the official journal of the American College of Medical Quality*. 2006; 21(6 Suppl):7S–16S. [PubMed: 17077414]
8. Warren DK, Quadir WW, Hollenbeak CS, Elward AM, Cox MJ, Fraser VJ. Attributable cost of catheter-associated bloodstream infections among intensive care patients in a nonteaching hospital. *Critical care medicine*. 2006; 34(8):2084–2089. [PubMed: 16763511]
9. Ashton CM, Kuykendall DH, Johnson ML, Wray NP, Wu L. The Association between the Quality of Inpatient Care and Early Readmission. *Annals of internal medicine*. 1995; 122(6):415–421. [PubMed: 7856989]
10. Jencks SF, Williams MV, Coleman EA. Rehospitalizations Among Patients in the Medicare Fee-for-Service Program. *The New England journal of medicine*. 2009; 360(14):1418–1428. [PubMed: 19339721]
11. Hasan M. Readmission of Patients to Hospital: Still Ill Defined and Poorly Understood. *International journal for quality in health care : journal of the International Society for Quality in Health Care / ISQua*. 2001; 13(3):177–179.
12. Tierney AJ, Worth A. Review: Readmission of Elderly Patients to Hospital. *Age and ageing*. 1995; 24(2):163–166. [PubMed: 7793340]
13. Victor CR, Vetter NJ. The Early Readmission of the Elderly to Hospital. *Age and ageing*. 1985; 14(1):37–42. [PubMed: 4003176]
14. Williams EI, Fitton F. Factors affecting early unplanned readmission of elderly patients to hospital. *Bmj*. 1988; 297(6651):784–787. [PubMed: 3142550]
15. Thomas JW, Holloway JJ. Investigating Early Readmission as an Indicator for Quality of Care Studies. *Medical care*. 1991; 29(4):377–394. [PubMed: 1902276]
16. Weinberger M, Oddone EZ, Henderson WG. Does Increased Access to Primary Care Reduce Hospital Readmissions? Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission. *The New England journal of medicine*. 1996; 334(22):1441–1447. [PubMed: 8618584]
17. Sreeramou P, Montie B, Ramirez AM, Ayeni A. Healthcare-Associated Infection: A Significant Cause of Hospital Readmission. *Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America*. 2010; 31(11):1195–1197.



18. Sherman ER, Heydon KH, St John KH, et al. Administrative Data Fail to Accurately Identify Cases of Healthcare-Associated Infection. *Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America*. 2006; 27(4):332–337.
19. Malpiedi, PJ.; Peterson, KD.; Soe, MM., et al. 2011 National and State Healthcare-Associated Infection Standardized Infection Ratio Report. Centers for Disease Control and Prevention; 2013 Feb 11.
20. Baggs, JM.; Scott, RD., II; Wise, ME., et al. Determining attributable Medicare reimbursement for central line associated bloodstream infections (CLABSI) reported to the National Healthcare Safety Network (NHSN). Paper presented at: ID Week 2012; San Diego, CA.
21. Yi SH, Baggs J, Gould CV, Scott RD 2nd, Jernigan JA. Medicare Reimbursement Attributable to Catheter-associated Urinary Tract Infection in the Inpatient Setting: A Retrospective Cohort Analysis. *Med Care*. 2014
22. Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and Non-central line-associated Bloodstream Infection). 2012. [http://www.cdc.gov/nhsn/pdfs/pscmanual/4psc\\_clabscurrent.pdf](http://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf)
23. Medicare. [Accessed September 12, 2012] 2012. <http://www.socialsecurity.gov/pubs/10043.html#a0=2>
24. Clinical Classifications Software (ICD-9-CM) [computer program]. Rockville, MD:
25. Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *Journal of clinical epidemiology*. 2011; 64(7):749–759. [PubMed: 21208778]
26. Kleinbaum, DG.; Klein, M. Logistic Regression A Self-Learning Text. 2nd Edition ed.. New York: Springer; 2002.
27. Emerson CB, Eyzaguirre LM, Albrecht JS, Comer AC, Harris AD, Furuno JP. Healthcare-Associated Infection and Hospital Readmission. *Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America*. 2012; 33(6):539–544.
28. Mattner F, Biertz F, Ziesing S, Gastmeier P, Chaberny IF. Long-term persistence of MRSA in re-admitted patients. *Infection*. 2010; 38(5):363–371. [PubMed: 20602144]
29. Murphy CR, Avery TR, Dubberke ER, Huang SS. Frequent Hospital Readmissions for Clostridium difficile Infection and the Impact on Estimates of Hospital-Associated C. difficile Burden. *Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America*. 2012; 33(1):20–28.
30. Kaboli PJ, Go JT, Hockenberry J, et al. Associations Between Reduced Hospital Length of Stay and 30-Day Readmission Rate and Mortality: 14-Year Experience in 129 Veterans Affairs Hospitals. *Annals of internal medicine*. 2012; 157(12):837–845. [PubMed: 23247937]
31. Goto M, Ohl ME, Schweizer ML, Perencevich EN. Accuracy of administrative code data for the surveillance of healthcare-associated infections: a systematic review and meta-analysis. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2014; 58(5):688–696. [PubMed: 24218103]
32. van Walraven C, Austin P. Administrative Database Research Has Unique Characteristics That Can Risk Biased Results. *Journal of clinical epidemiology*. 2012; 65(2):126–131. [PubMed: 22075111]
33. Scott RD 2nd, Sinkowitz-Cochran R, Wise ME, et al. CDC central-line bloodstream infection prevention efforts produced net benefits of at least \$640 Million during 1990–2008. *Health affairs*. 2014; 33(6):1040–1047. [PubMed: 24889954]
34. Dunagan WC, Woodward RS, Medoff G, et al. Antimicrobial Misuse in Patients With Positive Blood Cultures. *The American journal of medicine*. 1989; 87(3):253–259. [PubMed: 2773963]

**Table 1**

**Demographic and Clinical Characteristics of Study Population**

	Non-CLABSI		CLABSI		p-value <sup>†</sup>
	n=7180	88.7%	n=917	11.3%	
Follow up time <sup>††</sup>	447.7		48.0		----
Readmitted within 30 days	1920	26.7%	340	37.1%	<0.0001
Race					0.0001
White	6001	83.6%	739	80.6%	
Black	934	13.0%	160	17.5%	
Other	245	3.4%	18	2.0%	
Sex					0.654
Male	3749	52.2%	486	53.0%	
Age <sup>§</sup>	77.1	7.7	75.5	7.4	<0.0001
ICU Status <sup>§§</sup>	5035	70.1%	626	68.3%	0.248
Central line procedure code <sup>§§§</sup>	1850	25.8%	472	51.5%	<0.0001
Length of stay <sup>§§§</sup>					<0.0001
0–6 days	2157	30.0%	13	1.4%	
7–12 days	2461	34.3%	71	7.7%	
13–22 days	1618	22.5%	241	26.3%	
over 22 days	944	13.2%	592	64.6%	
Died within 30 days of discharge	818	11.4%	192	20.9%	<0.0001
Died after 30 days of discharge	1632	22.7%	241	26.3%	0.016
Co-morbidity score <sup>§§§</sup>					<0.0001
NA	420	5.9%	129	14.1%	
-1	369	5.1%	19	2.1%	
0	586	8.2%	21	2.3%	
1	1327	18.5%	154	16.8%	
2	1224	17.1%	212	23.1%	
3	1147	16.0%	163	17.8%	
>4	2107	29.4%	219	23.9%	

	Non-CLABSI	CLABSI	
Alzheimer's disease <sup>‡</sup>	632	72	7.9%
Alzheimer's disease and related disorders <sup>‡</sup>	1563	204	22.3%
Acute myocardial infarction <sup>‡</sup>	289	40	4.4%
Atrial fibrillation <sup>‡</sup>	1588	218	23.8%
Breast cancer <sup>‡</sup>	149	23	2.5%
Cataracts <sup>‡</sup>	1281	149	16.3%
Chronic heart failure <sup>‡</sup>	3712	525	57.3%
Chronic obstructive pulmonary disease <sup>‡</sup>	2311	307	33.5%
Depression <sup>‡</sup>	1358	202	22.0%
Diabetes <sup>‡</sup>	3157	435	47.4%
Endometrial cancer <sup>‡</sup>	25	10 <sup>‡</sup>	0.354
Glaucoma <sup>‡</sup>	647	75	8.2%
Hip/pelvic fracture <sup>‡</sup>	107	14	1.5%
Ischemic heart disease <sup>‡</sup>	4825	620	67.6%
Chronic kidney disease <sup>‡</sup>	2842	457	49.8%
Lung cancer <sup>‡</sup>	237	31	3.4%
Osteoporosis <sup>‡</sup>	891	90	9.8%
Prostate cancer <sup>‡</sup>	365	39	4.3%
Rheumatoid Arthritis <sup>‡</sup>	1832	242	26.4%
Rectal cancer <sup>‡</sup>	346	45	4.9%
Stroke or transient Ischemic attack <sup>‡</sup>	840	128	14.0%

<sup>‡</sup> P-values based on Chi-square tests

<sup>††</sup> Values expressed as person-years (PY)

<sup>§</sup> Values expressed as mean (standard deviation)

<sup>§§</sup> During the index CLABSI visit

<sup>‡</sup> CMS Chronic Conditions Categories

In accordance with the CMS data use agreement, the actual number and percentage were not displayed for cell sizes 10.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 2**

Most Frequent Primary ICD-9-CM Discharge CCS Category\* for the First Readmission Visit by CLABSI Status

CCS Category	Non-CLABSI		CLABSI	
Septicemia <sup>†</sup>	241	3.4%	63	6.9%
Complications of device <sup>†</sup>	83	1.2%	31	3.4%
Complications of surgical procedure	174	2.4%	26	2.8%
Pneumonia	97	1.4%	17	1.9%
Congestive heart failure	131	1.8%	13	1.4%
Respiratory failure; insufficiency	94	1.3%	12	1.3%
Urinary tract infections <sup>‡</sup>	41	0.6%	11	1.2%
Aspiration pneumonia	59	0.8%	10 <sup>¥</sup>	
Acute renal failure	63	0.9%	10 <sup>¥</sup>	
Gastrointestinal hemorrhage	53	0.7%	10 <sup>¥</sup>	
Intestinal Infection	42	0.6%	10 <sup>¥</sup>	
Intestinal obstruction without hernia <sup>‡</sup>	21	0.3%	10 <sup>¥</sup>	

<sup>†</sup> p < 0.0001;

<sup>‡</sup> p < 0.05

<sup>¥</sup> In accordance with the CMS data use agreement, the actual number and percentage were not displayed for cell sizes = 10.

Note: Table includes 12 CCS categories since for CLABSI, the 10<sup>th</sup> through 12<sup>th</sup> categories each contained an equal number of events.

\* - <http://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp>

**Table 3**

Final hazard ratios and 95% CI for CLABSI at the specific levels for the interaction terms, length of stay and rheumatoid arthritis, among patients who were readmitted within 30 days of the index hospitalization and for time to first readmission after index hospitalization

Readmission within 30 Days of the Index Hospitalization				
Length of stay <sup>§§</sup>	Rheumatoid arthritis			
	Yes		No	
	IRR	95% CI	IRR	95% CI
0–6 days	7.5	(4.0 14.4)	5.5	(2.9 10.6)
7–12 days	1.9	(1.2 3.0)	1.4	(0.9 2.2)
13–22 days	1.4	(1.0 1.9)	1.0	(0.8 1.3)
over 22 days <sup>†</sup>	1.3	(1.0 1.7)	1.0	(0.8 1.2)

  

First Readmission Regardless of Timing after Index Hospitalization				
Length of stay <sup>§§</sup>	Rheumatoid arthritis			
	Yes		No	
	IRR	95% CI	IRR	95% CI
0–6 days	3.8	(2.1 7.0)	3.0	(1.6 5.5)
7–12 days	1.6	(1.1 2.3)	1.3	(0.9 1.8)
13–22 days	1.3	(1.0 1.6)	1.0	(0.8 1.2)
over 22 days <sup>†</sup>	1.3	(1.0 1.5)	1.0	(0.9 1.1)

<sup>§§</sup>During the index CLABSI visit

<sup>†</sup>Reference category

\* Cox proportional hazards models were stratified by Gagne co-morbidity score and included age, sex, race, ICU status, central line procedure code, and CMS chronic conditions as co-variates. Terms for length of stay (LOS) and the CMS chronic condition rheumatoid arthritis and the effect modification by CLABSI for both of those terms were also included in the model.